{
  "url": "https://finance.yahoo.com/news/masimo-second-quarter-2025-earnings-132501284.html?.tsrc=rss",
  "authorsByline": "Simply Wall St",
  "articleId": "39af4c40e60443ca956d65813db1d8da",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-07T13:25:01+00:00",
  "addDate": "2025-08-07T14:24:41.507276+00:00",
  "refreshDate": "2025-08-07T14:24:41.507278+00:00",
  "score": 1.0,
  "title": "Masimo Second Quarter 2025 Earnings: EPS Misses Expectations",
  "description": "Masimo ( NASDAQ:MASI ) Second Quarter 2025 Results Key Financial Results Revenue: US$370.9m (down 25% from 2Q 2024...",
  "content": "\u2022 Profit margin: 12% (up from 3.2% in 2Q 2024).\n\u2022 EPS: US$0.83 (up from US$0.30 in 2Q 2024).\n\nWe've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%.\n\nLooking ahead, revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 8.2%.\n\nThe company's shares are down 7.3% from a week ago.\n\nIt's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Masimo, and understanding this should be part of your investment process.\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/D3A51B5A-270A-44C4-9B7E-59F5F0733EFB?blueprint=3969629&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://investor-research.typeform.com/to/wvg6MFri#feedback_token=Mzk2OTYyOTo2OTBjNzQwMzFkYjY5NWJm&company=Masimo&blueprintid=3969629",
    "https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global?blueprint=3969629&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=dividend-forecast-yield-6pcnt",
    "https://simplywall.st/markets/us/healthcare/medical-equipment?blueprint=3969629&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
    "https://simplywall.st/company/id/D3A51B5A-270A-44C4-9B7E-59F5F0733EFB/future?blueprint=3969629&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/MASI"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Simply Wall St",
      "weight": 0.08123457
    },
    {
      "name": "analyst estimates",
      "weight": 0.07814239
    },
    {
      "name": "analyst forecasts",
      "weight": 0.07752966
    },
    {
      "name": "next year",
      "weight": 0.07073851
    },
    {
      "name": "historical data",
      "weight": 0.069550216
    },
    {
      "name": "Revenue",
      "weight": 0.06891587
    },
    {
      "name": "revenue",
      "weight": 0.06891587
    },
    {
      "name": "revenues",
      "weight": 0.06891587
    },
    {
      "name": "investment risk",
      "weight": 0.06628343
    },
    {
      "name": "fundamental data",
      "weight": 0.065452956
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.98095703125
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97412109375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.966796875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.488525390625
    }
  ],
  "sentiment": {
    "positive": 0.05331421,
    "negative": 0.72021484,
    "neutral": 0.22680664
  },
  "summary": "Masimo's Q2 2025 earnings missed analyst estimates by 6.2% and its Q2 revenue was in line with analyst estimates. The company's shares are down 7.3% from a week ago. Looking ahead, revenue is expected to decline by 1.6% p.a. on average for the next three years, while revenues in the Medical Equipment industry in the US are expected to grow by 8.2%. However, Masimo shares have fallen 7. 3% since the previous week. The article by Simply Wall St provides commentary based on historical data and analyst forecasts only using an unbiased methodology and is not intended to be financial advice.",
  "shortSummary": "Masimo's Q2 earnings missed expectations by 6.2%, with revenue declining by 1.6%, but a 12% profit margin increase is still significant.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "bd1a371f6dbd483dbf87678ba1766a83",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global?blueprint=3969629&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=dividend-forecast-yield-6pcnt",
      "text": "Results\n21\nThese stocks are forecast to deliver over a 6% dividend yield next year. Their dividend payments are well covered by cash flows and they have been growing steadily. Perfect for income-focused investors seeking robust returns.\n21 companies\nColumbia Banking System\nMarket Cap: US$5.1b\nOperates as the Bank holding company of Umpqua Bank that provides banking, private banking, mortgage, and other financial services in the United States.\nCOLB\nUS$23.87\n7D\n-0.04%\n1Y\n3.4%\nOmega Healthcare Investors\nMarket Cap: US$12.2b\nA Real Estate Investment Trust (\u201cREIT\u201d) providing financing and capital to the long-term healthcare industry with a focus on skilled nursing and assisted living facilities located in the United States and the United Kingdom.\nOHI\nUS$40.35\n7D\n3.9%\n1Y\n8.2%\nFlowers Foods\nMarket Cap: US$3.4b\nProduces and markets packaged bakery food products in the United States.\nFLO\nUS$15.97\n7D\n0.3%\n1Y\n-29.0%\nVerizon Communications\nMarket Cap: US$179.9b\nThrough its subsidiaries, engages in the provision of communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities worldwide.\nVZ\nUS$42.35\n7D\n-0.6%\n1Y\n5.1%\nCitizens & Northern\nMarket Cap: US$286.4m\nOperates as the bank holding company for Citizens & Northern Bank that provides various banking and related services to individual and corporate customers.\nCZNC\nUS$18.55\n7D\n-1.7%\n1Y\n4.1%\nLCNB\nMarket Cap: US$208.9m\nOperates as the financial holding company for LCNB National Bank that provides banking services in the United States.\nLCNB\nUS$14.50\n7D\n-3.1%\n1Y\n7.5%\nCopa Holdings\nMarket Cap: US$4.6b\nThrough its subsidiaries, provides airline passenger and cargo transport services.\nCPA\nUS$112.12\n7D\n1.7%\n1Y\n35.1%\nConagra Brands\nMarket Cap: US$9.0b\nOperates as a consumer packaged goods food company primarily in the United States.\nCAG\nUS$18.93\n7D\n2.2%\n1Y\n-36.4%\nBrookline Bancorp\nMarket Cap: US$923.1m\nOperates as a bank holding company for the Brookline Bank that provides commercial, business, and retail banking products and services to corporate, municipal, and retail customers in the United States.\nBRKL\nUS$10.17\n7D\n-3.2%\n1Y\n6.6%\nArtisan Partners Asset Management\nMarket Cap: US$3.8b\nArtisan Partners Asset Management Inc. is publicly owned investment manager.\nAPAM\nUS$46.26\n7D\n3.7%\n1Y\n21.6%\nTFS Financial\nMarket Cap: US$3.6b\nThrough its subsidiaries, provides retail consumer banking services in the United States.\nTFSL\nUS$12.72\n7D\n0.9%\n1Y\n0.2%\nXP\nMarket Cap: US$8.9b\nProvides financial products and services in Brazil.\nXP\nUS$17.14\n7D\n4.4%\n1Y\n2.7%\nUnited Parcel Service\nMarket Cap: US$73.5b\nA package delivery and logistics provider, offers transportation and delivery services.\nUPS\nUS$86.25\n7D\n-1.1%\n1Y\n-30.1%\nBanco Latinoamericano de Comercio Exterior S. A\nMarket Cap: US$1.5b\nBanco Latinoamericano de Comercio Exterior, S.\nBLX\nUS$41.30\n7D\n1.6%\n1Y\n46.5%\nCricut\nMarket Cap: US$1.0b\nEngages in the design, marketing, and distribution of a creativity platform that enables users to turn ideas into professional-looking handmade goods in the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand, Western Europe, the Middle East, Latin America, South Africa, and Asia.\nCRCT\nUS$5.67\n7D\n15.2%\n1Y\n-10.1%\nBuckle\nMarket Cap: US$2.5b\nOperates as a retailer of casual apparel, footwear, and accessories for men, women, and kids under the Buckle and Buckle Youth brands in the United States.\nBKE\nUS$51.74\n7D\n4.8%\n1Y\n30.9%\nGlobal Ship Lease\nMarket Cap: US$1.0b\nEngages in owning and chartering of containerships under fixed-rate charters to container shipping companies worldwide.\nGSL\nUS$30.34\n7D\n6.0%\n1Y\n13.1%\nMacy's\nMarket Cap: US$3.3b\nAn omni-channel retail organization, operates stores, websites, and mobile applications in the United States.\nM\nUS$12.11\n7D\n-7.0%\n1Y\n-20.4%\nOxford Industries\nMarket Cap: US$585.9m\nAn apparel company, designs, sources, markets, and distributes lifestyle products worldwide.\nOXM\nUS$38.78\n7D\n-0.03%\n1Y\n-58.6%\nMarket Cap: US$2.4b\nThrough its subsidiaries, operates as a social media platform for people to create, discover, and distribute content in the People\u2019s Republic of China.\nWB\nUS$9.75\n7D\n-0.9%\n1Y\n28.5%\nSila Realty Trust\nMarket Cap: US$1.4b\nSila Realty Trust, Inc., headquartered in Tampa, Florida, is a net lease real estate investment trust with a strategic focus on investing in the growing and resilient healthcare sector.\nSILA\nUS$25.41\n7D\n3.9%\n1Y\n13.7%"
    },
    {
      "url": "https://simplywall.st/company/id/D3A51B5A-270A-44C4-9B7E-59F5F0733EFB/future?blueprint=3969629&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Masimo Future Growth\nFuture criteria checks 3/6\nMasimo's revenue is forecast to decline at 1.6% per annum while its annual earnings are expected to grow at 49.4% per year. EPS is expected to grow by 50.4% per annum.\nKey information\n49.4%\nEarnings growth rate\n50.35%\nEPS growth rate\n| Medical Equipment earnings growth | 12.3% |\n| Revenue growth rate | -1.6% |\n| Future return on equity | n/a |\n| Analyst coverage | Good |\n| Last updated | 06 Aug 2025 |\nRecent future growth updates\nRecent updates\nCalculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)\nAug 01Masimo Corporation: A Much Cleaner Picture\nJun 23Is Masimo (NASDAQ:MASI) Using Too Much Debt?\nJun 19Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?\nMay 29Masimo: Priced Dearly Given Uncertainty\nApr 25Pinning Down Masimo Corporation's (NASDAQ:MASI) P/S Is Difficult Right Now\nApr 24An Intrinsic Calculation For Masimo Corporation (NASDAQ:MASI) Suggests It's 34% Undervalued\nFeb 17At US$178, Is Masimo Corporation (NASDAQ:MASI) Worth Looking At Closely?\nJan 30Masimo: A Stellar Performance After The Dust Has Settled\nDec 11Here's Why Masimo (NASDAQ:MASI) Has A Meaningful Debt Burden\nNov 28Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 44% Undervaluation?\nNov 07Masimo Corporation's (NASDAQ:MASI) 28% Share Price Surge Not Quite Adding Up\nOct 15Masimo Corporation: Too Much Uncertainty For Now\nSep 25Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph\nIncreased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Masimo: Promising Developments\nMay 12Baron Funds - Masimo Corp.: Can Potentially Double Our Investment\nMay 05Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 12/31/2027 | 1,775 | 297 | N/A | N/A | 6 |\n| 12/31/2026 | 1,639 | 249 | 355 | N/A | 8 |\n| 12/31/2025 | 1,521 | 200 | 339 | N/A | 8 |\n| 6/29/2025 | 2,154 | -270 | 134 | 177 | N/A |\n| 3/29/2025 | 2,127 | -290 | 137 | 182 | N/A |\n| 12/28/2024 | 2,094 | -305 | 145 | 196 | N/A |\n| 9/28/2024 | 1,889 | 92 | 158 | 223 | N/A |\n| 6/29/2024 | 1,864 | 93 | 119 | 190 | N/A |\n| 3/30/2024 | 1,823 | 92 | 59 | 140 | N/A |\n| 12/30/2023 | 2,048 | 82 | 6 | 94 | N/A |\n| 9/30/2023 | 2,116 | 89 | -58 | 10 | N/A |\n| 7/1/2023 | 2,187 | 116 | -28 | 28 | N/A |\n| 4/1/2023 | 2,297 | 118 | -45 | 7 | N/A |\n| 12/31/2022 | 2,036 | 144 | -27 | 29 | N/A |\n| 10/1/2022 | 1,746 | 171 | 78 | 134 | N/A |\n| 7/2/2022 | 1,505 | 191 | 147 | 205 | N/A |\n| 4/2/2022 | 1,244 | 223 | 181 | 229 | N/A |\n| 1/1/2022 | 1,239 | 230 | 230 | 265 | N/A |\n| 10/2/2021 | 1,207 | 232 | 188 | 232 | N/A |\n| 7/3/2021 | 1,177 | 224 | 149 | 190 | N/A |\n| 4/3/2021 | 1,173 | 229 | 176 | 228 | N/A |\n| 1/2/2021 | 1,144 | 240 | 131 | 211 | N/A |\n| 9/26/2020 | 1,096 | 223 | 138 | 217 | N/A |\n| 6/27/2020 | 1,047 | 222 | 148 | 227 | N/A |\n| 3/28/2020 | 976 | 211 | 119 | 222 | N/A |\n| 12/28/2019 | 938 | 196 | 149 | 222 | N/A |\n| 9/28/2019 | 913 | 190 | 150 | 215 | N/A |\n| 6/29/2019 | 895 | 198 | 153 | 212 | N/A |\n| 3/30/2019 | 877 | 197 | N/A | 210 | N/A |\n| 12/29/2018 | 858 | 194 | N/A | 240 | N/A |\n| 9/29/2018 | 843 | 139 | N/A | 225 | N/A |\n| 6/30/2018 | 826 | 118 | N/A | 199 | N/A |\n| 3/31/2018 | 807 | 119 | N/A | 114 | N/A |\n| 12/30/2017 | 790 | 125 | N/A | 56 | N/A |\n| 9/30/2017 | 766 | 348 | N/A | 338 | N/A |\n| 7/1/2017 | 740 | 340 | N/A | 347 | N/A |\n| 4/1/2017 | 720 | 325 | N/A | 414 | N/A |\n| 12/31/2016 | 713 | 311 | N/A | 419 | N/A |\n| 10/1/2016 | 672 | 109 | N/A | 150 | N/A |\n| 7/2/2016 | 657 | 101 | N/A | 145 | N/A |\n| 4/2/2016 | 640 | 90 | N/A | 117 | N/A |\n| 1/2/2016 | 623 | 83 | N/A | 117 | N/A |\n| 10/3/2015 | 623 | 80 | N/A | 85 | N/A |\n| 7/4/2015 | 613 | 76 | N/A | 86 | N/A |\n| 4/4/2015 | 596 | 70 | N/A | 91 | N/A |\n| 1/3/2015 | 580 | 73 | N/A | 96 | N/A |\n| 9/27/2014 | 556 | 61 | N/A | 73 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: MASI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).\nEarnings vs Market: MASI is forecast to become profitable over the next 3 years, which is considered above average market growth.\nHigh Growth Earnings: MASI is expected to become profitable in the next 3 years.\nRevenue vs Market: MASI's revenue is expected to decline over the next 3 years (-1.6% per year).\nHigh Growth Revenue: MASI's revenue is forecast to decline over the next 3 years (-1.6% per year).\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: Insufficient data to determine if MASI's Return on Equity is forecast to be high in 3 years time\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/06 10:39 |\n| End of Day Share Price | 2025/08/06 00:00 |\n| Earnings | 2025/06/29 |\n| Annual Earnings | 2024/12/28 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nMasimo Corporation is covered by 29 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Michael Polark | Baird |\n| Ishan Majumdar | Baptista Research |\n| Charley Jones | Barrington Research Associates, Inc. |"
    },
    {
      "url": "https://simplywall.st/markets/us/healthcare/medical-equipment?blueprint=3969629&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
      "text": "Over the last 7 days, the Medical Equipment industry has dropped 2.7%, driven by pullbacks in Stryker and Intuitive Surgical of 6.4% and 5.3%, respectively. Over the past 12 months, the industry was up 7.7%. Earnings are forecast to grow by 12% annually.\nHas the U.S. Medical Equipment Industry valuation changed over the past few years?\n| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |\n|---|---|---|---|---|---|---|\n| Thu, 07 Aug 2025 | US$1.3t | US$290.7b | US$31.4b | 29.3x | 42x | 4.5x |\n| Sat, 05 Jul 2025 | US$1.4t | US$286.7b | US$29.6b | 30.8x | 46x | 4.7x |\n| Mon, 02 Jun 2025 | US$1.3t | US$286.7b | US$29.6b | 31.9x | 45.3x | 4.7x |\n| Wed, 30 Apr 2025 | US$1.3t | US$284.4b | US$28.3b | 31.6x | 46.1x | 4.6x |\n| Fri, 28 Mar 2025 | US$1.3t | US$283.3b | US$27.4b | 28.7x | 48.3x | 4.7x |\n| Sun, 23 Feb 2025 | US$1.4t | US$282.5b | US$30.1b | 31.7x | 46.7x | 5x |\n| Tue, 21 Jan 2025 | US$1.4t | US$284.0b | US$23.1b | 36.4x | 59.2x | 4.8x |\n| Thu, 19 Dec 2024 | US$1.3t | US$284.0b | US$23.6b | 34.4x | 55.9x | 4.6x |\n| Sat, 16 Nov 2024 | US$1.3t | US$283.1b | US$22.9b | 36.9x | 57.6x | 4.7x |\n| Mon, 14 Oct 2024 | US$1.3t | US$279.4b | US$22.1b | 37x | 59.2x | 4.7x |\n| Wed, 11 Sep 2024 | US$1.3t | US$279.6b | US$22.2b | 38x | 58.9x | 4.7x |\n| Fri, 09 Aug 2024 | US$1.2t | US$279.4b | US$21.9b | 35.9x | 55.4x | 4.3x |\n| Sun, 07 Jul 2024 | US$1.2t | US$276.4b | US$22.7b | 36.9x | 54.4x | 4.5x |\n| Tue, 04 Jun 2024 | US$1.2t | US$276.3b | US$22.7b | 37.4x | 54.5x | 4.5x |\n| Thu, 02 May 2024 | US$1.2t | US$276.1b | US$24.6b | 35.9x | 50.2x | 4.5x |\n| Sat, 30 Mar 2024 | US$1.3t | US$265.9b | US$22.6b | 40.9x | 58.1x | 4.9x |\n| Mon, 26 Feb 2024 | US$1.3t | US$265.9b | US$22.7b | 35.8x | 56.7x | 4.8x |\n| Wed, 24 Jan 2024 | US$1.2t | US$267.4b | US$20.2b | 38.5x | 61.9x | 4.7x |\n| Fri, 22 Dec 2023 | US$1.2t | US$267.4b | US$20.2b | 37.4x | 58.6x | 4.4x |\n| Sun, 19 Nov 2023 | US$1.1t | US$267.0b | US$19.7b | 35.2x | 56.2x | 4.1x |\n| Tue, 17 Oct 2023 | US$1.1t | US$263.9b | US$15.1b | 33.2x | 69.8x | 4x |\n| Thu, 14 Sep 2023 | US$1.2t | US$263.8b | US$15.0b | 34.1x | 77.9x | 4.4x |\n| Sat, 12 Aug 2023 | US$1.2t | US$263.4b | US$15.1b | 35.4x | 80.1x | 4.6x |\n| Mon, 10 Jul 2023 | US$1.3t | US$260.7b | US$16.2b | 36.8x | 77.7x | 4.8x |\n| Wed, 07 Jun 2023 | US$1.2t | US$261.2b | US$16.2b | 36.5x | 75.4x | 4.7x |\n| Fri, 05 May 2023 | US$1.3t | US$260.3b | US$16.7b | 37.7x | 75x | 4.8x |\n| Sun, 02 Apr 2023 | US$1.2t | US$260.2b | US$18.5b | 35.9x | 64.4x | 4.6x |\n| Tue, 28 Feb 2023 | US$1.1t | US$259.7b | US$18.7b | 38.5x | 61.5x | 4.4x |\n| Thu, 26 Jan 2023 | US$1.2t | US$262.5b | US$20.8b | 34.6x | 56.5x | 4.5x |\n| Sat, 24 Dec 2022 | US$1.1t | US$244.4b | US$19.0b | 31.9x | 58.5x | 4.5x |\n| Mon, 21 Nov 2022 | US$1.1t | US$244.5b | US$20.0b | 32.3x | 54.3x | 4.4x |\n| Wed, 19 Oct 2022 | US$1.0t | US$244.4b | US$26.5b | 32.2x | 39.5x | 4.3x |\n| Fri, 16 Sep 2022 | US$1.1t | US$244.6b | US$26.3b | 33.6x | 42.5x | 4.6x |\n| Sun, 14 Aug 2022 | US$1.2t | US$245.5b | US$26.7b | 34.4x | 44.1x | 4.8x |\n44.1x\nWhich industries have driven the changes within the U.S. Healthcare industry?\n| US Market | -0.16% | |\n| Healthcare | -2.74% | |\n| Medical Equipment | -2.72% | |\n| Medical Equipment | -2.69% | |\n| Medical Supplies | -3.25% |\nWhich companies have driven the market over the last 7 days?\n| Company | Last Price | 7D | 1Y | Valuation | |\n|---|---|---|---|---|---|\n| ABT Abbott Laboratories | US$130.93 | 1.9% +US$4.1b | 19.1% | PE16.4x | |\n| IDXX IDEXX Laboratories | US$624.19 | 9.1% +US$3.9b | 33.6% | PE50.7x | |\n| TMDX TransMedics Group | US$125.74 | 19.9% +US$739.7m | -19.4% | PE59.8x | |\n| ATEC Alphatec Holdings | US$15.20 | 41.7% +US$680.9m | 149.2% | PS3.3x | |\n| ALGN Align Technology | US$136.90 | 6.1% +US$571.9m | -36.1% | PE22.7x |"
    },
    {
      "url": "https://simplywall.st/company/id/D3A51B5A-270A-44C4-9B7E-59F5F0733EFB?blueprint=3969629&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Masimo (MASI) Stock Overview\nDevelops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 3/6 |\n| Future Growth | 3/6 |\n| Past Performance | 0/6 |\n| Financial Health | 3/6 |\n| Dividends | 0/6 |\nMASI Community Fair Values\nSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.\nMasimo Corporation Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | US$144.65 |\n| 52 Week High | US$194.88 |\n| 52 Week Low | US$107.98 |\n| Beta | 1.21 |\n| 1 Month Change | -10.96% |\n| 3 Month Change | -5.81% |\n| 1 Year Change | 17.82% |\n| 3 Year Change | -8.32% |\n| 5 Year Change | -31.56% |\n| Change since IPO | 592.11% |\nRecent News & Updates\nRecent updates\nCalculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)\nAug 01Masimo Corporation: A Much Cleaner Picture\nJun 23Is Masimo (NASDAQ:MASI) Using Too Much Debt?\nJun 19Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?\nMay 29Masimo: Priced Dearly Given Uncertainty\nApr 25Pinning Down Masimo Corporation's (NASDAQ:MASI) P/S Is Difficult Right Now\nApr 24An Intrinsic Calculation For Masimo Corporation (NASDAQ:MASI) Suggests It's 34% Undervalued\nFeb 17At US$178, Is Masimo Corporation (NASDAQ:MASI) Worth Looking At Closely?\nJan 30Masimo: A Stellar Performance After The Dust Has Settled\nDec 11Here's Why Masimo (NASDAQ:MASI) Has A Meaningful Debt Burden\nNov 28Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 44% Undervaluation?\nNov 07Masimo Corporation's (NASDAQ:MASI) 28% Share Price Surge Not Quite Adding Up\nOct 15Masimo Corporation: Too Much Uncertainty For Now\nSep 25Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph\nIncreased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Masimo: Promising Developments\nMay 12Baron Funds - Masimo Corp.: Can Potentially Double Our Investment\nMay 05Shareholder Returns\n| MASI | US Medical Equipment | US Market | |\n|---|---|---|---|\n| 7D | -7.3% | -2.7% | -0.2% |\n| 1Y | 17.8% | 7.7% | 22.4% |\nReturn vs Industry: MASI exceeded the US Medical Equipment industry which returned 8.4% over the past year.\nReturn vs Market: MASI underperformed the US Market which returned 21.3% over the past year.\nPrice Volatility\n| MASI volatility | |\n|---|---|\n| MASI Average Weekly Movement | 6.1% |\n| Medical Equipment Industry Average Movement | 8.4% |\n| Market Average Movement | 6.5% |\n| 10% most volatile stocks in US Market | 17.6% |\n| 10% least volatile stocks in US Market | 3.1% |\nStable Share Price: MASI has not had significant price volatility in the past 3 months compared to the US market.\nVolatility Over Time: MASI's weekly volatility (6%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1989 | 3,600 | Katie Szyman | www.masimo.com |\nMasimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions.\nMasimo Corporation Fundamentals Summary\n| MASI fundamental statistics | |\n|---|---|\n| Market cap | US$8.89b |\n| Earnings (TTM) | -US$269.70m |\n| Revenue (TTM) | US$2.15b |\nIs MASI overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| MASI income statement (TTM) | |\n|---|---|\n| Revenue | US$2.15b |\n| Cost of Revenue | US$1.10b |\n| Gross Profit | US$1.06b |\n| Other Expenses | US$1.33b |\n| Earnings | -US$269.70m |\nLast Reported Earnings\nJun 29, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -4.97 |\n| Gross Margin | 49.11% |\n| Net Profit Margin | -12.52% |\n| Debt/Equity Ratio | 57.4% |\nHow did MASI perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/06 10:39 |\n| End of Day Share Price | 2025/08/06 00:00 |\n| Earnings | 2025/06/29 |\n| Annual Earnings | 2024/12/28 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nMasimo Corporation is covered by 29 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Michael Polark | Baird |\n| Ishan Majumdar | Baptista Research |\n| Charley Jones | Barrington Research Associates, Inc. |"
    }
  ],
  "argos_summary": "Masimo Corporation reported a profit margin increase to 12% and earnings per share (EPS) of $0.83, up from $0.30 in the previous quarter. However, revenue is expected to decline by 1.6% annually over the next three years, contrasting with an 8.2% growth forecast for the Medical Equipment industry. The company's shares have decreased by 7.3% recently, and it has been identified with one warning sign that investors should consider.",
  "argos_id": "MCZ3ZE61D"
}